Basic Sildalis Information

• INN (International Nonproprietary Name): Sildalis does not have an official INN; it is a combination medication containing sildenafil citrate (INN: sildenafil) and tadalafil (INN: tadalafil).
• Brand Names Available In United Kingdom: Sildalis is marketed as a non-innovator, mostly internet-sold combination drug that merges the active ingredients of Viagra (sildenafil) and Cialis (tadalafil); packaging commonly shows red, oval tablets and is supplied via online pharmacies and unofficial distributors rather than registered local pharmacies.
• ATC Code: G04BE03 (sildenafil) and G04BE08 (tadalafil).
• Forms & Dosages: Tablet; typical strength sold is 100mg sildenafil + 20mg tadalafil in blister packs of 6–20.
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Not registered with major national drug agencies as a fixed sildenafil+tadalafil combination product; no public regulatory listing exists for Sildalis as a combined preparation.
• OTC / Rx Classification: Prescription only (Rx) where sildenafil or tadalafil are regulated, although Sildalis is widely sold without prescription via online shops operating outside regulated supply chains.

Key Findings From Recent Trials

Major 2022–2025 Studies

Patients commonly ask whether Sildalis has the same evidence base as Viagra or Cialis, and the short answer is: no.

No randomised controlled trials or regulatory submissions exist for a fixed sildenafil+tadalafil combination product labelled Sildalis.

The strongest published evidence covers the two individual agents, sildenafil and tadalafil, from multiple RCTs and meta-analyses between 2020 and 2024.

Those syntheses show clinically meaningful improvements in erectile function scores versus placebo for both sildenafil and tadalafil.

Sildenafil trials consistently report a rapid onset, with peak effect within roughly one hour.

Tadalafil trials emphasise a longer duration of action, with efficacy sustained up to 36 hours in many studies.

Main Outcomes

Meta-analyses indicate that sildenafil produces quick, reliable improvements in erection rigidity and timeliness for on-demand use.

Tadalafil provides a prolonged therapeutic window that many patients describe as more spontaneous sexual opportunity.

Combining both agents in theory could broaden onset and duration, but no clinical trials validate that benefit for Sildalis specifically.

Because Sildalis lacks trial data, any claimed superiority is anecdotal and not supported by regulatory evidence.

Safety Observations

Pooled safety signals for the individual drugs emphasise vasodilatory adverse events such as headache and flushing.

Sildenafil is more commonly associated with transient visual disturbances, including a bluish tinge or blurred vision.

Tadalafil more commonly causes muscle and back pain, reflecting its pharmacologic profile.

Serious but rare events reported for PDE5 inhibitors in general include non-arteritic anterior ischaemic optic neuropathy, severe hypotension, syncope and priapism.

For Sildalis specifically, there are no published pharmacokinetic or safety trials, so additive or synergistic adverse events remain unquantified and regulatory approval is absent.

Research-First Summary

Clinicians should base decisions on the established evidence for sildenafil and tadalafil individually rather than on untested combinations like Sildalis.

Regulatory agencies list no approved sildenafil+tadalafil fixed‑dose products, so safety and efficacy claims for Sildalis are unsupported by formal RCTs or submissions.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how two erection pills in one tablet are supposed to help.

Sildalis combines a fast‑acting drug and a long‑acting drug so, in theory, you get both a quick start and a longer window to be intimate.

Sildenafil relaxes blood vessels quickly to allow blood in, and tadalafil keeps the effect going for many hours.

Scientific Breakdown

Both sildenafil and tadalafil are phosphodiesterase type 5 (PDE5) inhibitors that prevent the breakdown of cyclic GMP in penile smooth muscle.

Increased cyclic GMP amplifies the nitric oxide pathway, producing vasodilation of the corpus cavernosum and facilitating erection with sexual stimulation.

Sildenafil has a relatively short to moderate half‑life, with onset around 30–60 minutes and duration of several hours.

Tadalafil has a substantially longer half‑life of about 17.5 hours, allowing effects that can last up to 36 hours for some patients.

Molecular Targets

PDE5 selectivity reduces cGMP breakdown specifically in the corpus cavernosum, which is why both drugs are effective for erectile dysfunction.

Pharmacodynamic Implications

Combining the agents could theoretically broaden the onset and duration of effect.

However, overlapping vasodilatory effects increase the risk of additive adverse events such as headache, flushing and hypotension.

No formal pharmacokinetic or pharmacodynamic studies exist for Sildalis; therefore the interaction profile remains unpredictable.

This uncertainty underpins clinical caution in recommending unregulated combinations.

Scope Of Approved And Off-Label Use

United Kingdom Approvals

Sildalis is not an MHRA‑approved combination product and has no public regulatory listing as a fixed sildenafil+tadalafil formulation.

Individually, sildenafil (for example, Viagra and the OTC Viagra Connect pathway) and tadalafil (for example, Cialis and Cialis Daily) are authorised for erectile dysfunction in the UK.

Tadalafil also has licensed indications for benign prostatic hyperplasia and formulations for pulmonary arterial hypertension exist separately.

Notable Off-Label Trends

Online markets and direct‑to‑consumer suppliers commonly sell Sildalis as an “enhanced potency” or “double action” pill, often without prescription checks.

Manufacturers are largely outside established Western supply chains, frequently tracing back to Indian generic producers or direct‑to‑web suppliers.

Clinicians warn that unsupervised use is risky because combined dosing may exceed safer therapeutic exposure and interactions cannot be reliably predicted.

Importing prescription‑only medicines without a valid prescription is discouraged in the UK and can carry legal and safety implications.

Dosage Strategy

General Dosing

Commercial Sildalis preparations are typically 100mg sildenafil + 20mg tadalafil per tablet.

The marketed recommendation is one tablet 30–60 minutes before sexual activity, not more than once in 24 hours.

This fixed strength exceeds usual starting doses for either agent alone; sildenafil commonly starts at 25–50mg, and tadalafil often starts at 10mg for on‑demand or 5mg for daily therapy.

Because the tablet combines two high‑strength agents, the starting exposure is higher than standard practice for many patients.

Condition-Specific Dosing

Sildalis is promoted for erectile dysfunction only and should not be used for other licensed indications of tadalafil without clinical oversight.

Neither children nor adolescents should use Sildalis; it is not approved or studied in paediatric populations.

Elderly patients and those with liver or renal impairment normally require dose reduction when taking sildenafil or tadalafil individually; Sildalis‑specific guidance is not available.

Clinicians should individualise therapy using single authorised agents under GP or urologist supervision rather than recommending unregulated fixed combinations.

Safety Protocols

Contraindications

Absolute contraindications include known allergy to sildenafil, tadalafil or any excipients.

Concurrent use with nitrates such as glyceryl trinitrate, isosorbide mononitrate or recreational amyl nitrite (“poppers”) is an absolute contraindication due to risk of life‑threatening hypotension.

Use with riociguat is also contraindicated.

Patients with cardiovascular instability that renders sexual activity unsafe should not use PDE5 inhibitors.

Adverse Effects

Common mild to moderate adverse effects include headache, flushing, nasal congestion, dizziness and indigestion.

Sildenafil is particularly associated with transient visual disturbances such as a bluish tint or blurred vision.

Tadalafil is more commonly linked to muscle and back pain.

Rare but serious events include non‑arteritic anterior ischaemic optic neuropathy (NAION), severe hypotension, syncope and priapism requiring emergency treatment.

Combining two PDE5 inhibitors theoretically magnifies these risks, and no formal safety dataset quantifies those additive effects for Sildalis.

UK guidance recommends cardiovascular risk assessment and a medication review before initiating any PDE5 therapy.

Interaction Mapping

Food Interactions

High‑fat meals may delay oral sildenafil onset, which can blunt its rapid‑onset advantage.

Tadalafil absorption is less affected by food, so timing around meals is generally more flexible.

Large amounts of grapefruit or grapefruit juice can inhibit CYP3A4 and may raise PDE5 inhibitor levels; exercise caution with significant grapefruit intake.

Drug Combinations To Avoid

Avoid concurrent nitrates for any cause because of the risk of profound hypotension.

Do not combine with riociguat, which is contraindicated.

Caution is required with alpha‑blockers, as additive blood pressure lowering can cause symptomatic orthostatic hypotension.

CYP3A4 inhibitors such as certain azole antifungals, protease inhibitors and some macrolide antibiotics can increase PDE5 levels and necessitate dose adjustment or avoidance.

Over‑the‑counter or herbal “sexual enhancers” may contain undisclosed nitrates or PDE5 agents and therefore pose a particular danger when combined with Sildalis.

Because Sildalis increases cumulative PDE5 exposure, all interaction risks are magnified and remain clinically unquantified for the combination product.

Patient Experience Analysis

Survey Data

There are no peer‑reviewed patient surveys specifically for Sildalis; published patient‑reported outcome studies focus on sildenafil and tadalafil separately.

Broadly, users of sildenafil report rapid onset and reliable on‑demand efficacy in clinical studies, while tadalafil users report longer spontaneity and satisfaction tied to prolonged effect.

Forum Trends

Monitoring of online forums and user reviews shows recurring themes: perceived stronger or longer erections when using combination products, and a higher incidence of headaches, flushing and prolonged side effects.

Many purchasers obtain Sildalis via online suppliers or unregulated distributors, where packaging and product authenticity vary.

Clinicians report under‑reporting of adverse events when drugs are obtained outside healthcare pathways and advise patients to consult GPs or sexual health clinics rather than self‑medicate.

Distribution And Pricing Landscape

Sildalis is predominantly sold through online pharmacies and unofficial distributors rather than regulated UK pharmacy chains.

Manufacturing is commonly attributed to Indian generic companies or direct‑to‑web suppliers and it is not part of mainstream Western pharmaceutical supply chains.

Internet listings often undercut branded Viagra and Cialis prices, which increases demand but also correlates with higher counterfeit risk.

Buying prescription medicines without a valid prescriber is discouraged; legal importation for personal use remains subject to prescription rules.

In our online pharmacy, sildalis is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

Alternative Options

Comparison Table

Sildalis (100mg sildenafil + 20mg tadalafil): marketed as dual action but unapproved.

Pros: Perceived broader therapeutic window by users.

Cons: Untested combination, higher potential adverse‑event risk, regulatory absence and uncertain pharmacokinetics.

Viagra (sildenafil, Pfizer): Pros: well studied and MHRA‑authorised; predictable dosing and known onset.

Cons: Shorter duration of action compared with tadalafil.

Cialis (tadalafil, Eli Lilly): Pros: long duration (up to 36 hours) and licensed daily formulations.

Cons: Prolonged adverse effects and a need for dose adjustment in hepatic or renal impairment.

Generics: Pros: lower cost if supplied via licensed UK pharmacies and subject to regulatory standards.

Cons: Variable quality if bought from unverified online sellers.

Clinical Pros And Cons

Using single authorised agents allows dose titration and safety monitoring tailored to the patient.

Fixed‑dose combinations remove flexibility and complicate dose adjustments for elderly patients or those with comorbidity.

Practical Guidance

Prefer MHRA‑licensed products prescribed or dispensed via regulated UK channels.

Avoid unregistered combination products and discuss erectile dysfunction openly with a GP or sexual health clinic for safe, evidence‑based treatment.

Regulatory Status

Sildalis is not registered with the FDA, EMA, MHRA or other major national drug agencies as a combination product.

Both sildenafil and tadalafil have distinct ATC codes (sildenafil G04BE03; tadalafil G04BE08) and are individually authorised for erectile dysfunction.

Despite prescription‑only status in regulated jurisdictions, Sildalis is commonly sold without prescription online and therefore falls outside established regulatory oversight.

Healthcare professionals should report adverse events associated with unregulated products to the MHRA Yellow Card scheme if patients present after using them.

Consolidated FAQ

Common Questions & Short Answers

Is Sildalis approved in the UK?

No — there is no MHRA approval for a fixed sildenafil+tadalafil combination; both active agents have separate approvals.

Is it safe to buy online?

Buying online without prescription is risky because it can bypass safety checks and increase the chance of counterfeit or adulterated products.

How should it be dosed?

Marketed strength is 100mg sildenafil + 20mg tadalafil, taken 30–60 minutes before sex, maximum once per 24 hours, but this exceeds recommended starting doses for many patients.

What are the biggest dangers?

Concurrent nitrate use causing severe hypotension, unassessed drug interactions, priapism and unknown pharmacokinetics of the combination.

Who should avoid it?

Patients taking nitrates or riociguat, those with unstable cardiovascular disease, and people with severe hepatic or renal impairment should avoid it.

What to do if adverse events occur?

Seek urgent medical attention for severe hypotension, syncope or priapism, and report adverse reactions via the Yellow Card scheme.

Visual Guide

Suggested Diagrams & Captions

Include an efficacy timeline overlay showing sildenafil onset/duration versus tadalafil, captioned “Sildenafil: Rapid Onset; Tadalafil: Prolonged Action.”

Design a contraindication flowchart to screen for nitrates, riociguat and cardiovascular risk before prescribing PDE5 inhibitors.

Create a supply‑chain map comparing a legitimate UK pharmacy supply route with online importers and unverified suppliers, highlighting counterfeit risk.

Use adverse‑event icons for headache, flushing, visual change and priapism with brief management notes and MHRA signposting.

Always add alt text and simple language callouts so patient audiences can understand the graphics.

Storage And Transport

Store tablets below 30°C, away from moisture and direct sunlight, and keep out of reach of children.

Ensure sealed blister packs and legitimate supply documentation when receiving prescription medicines.

Temperature excursions during shipping — especially from hot climates — can degrade potency, which is a particular concern for online imports.

Advise patients to discard tablets with damaged packaging or unusual odour or appearance.

Guidelines For Proper Use

Clinical Checklist

Confirm an erectile dysfunction diagnosis and assess cardiovascular safety for sexual activity.

Review current medications for nitrates, riociguat and CYP3A4 modulators.

Start with individually authorised agents at recommended starting doses rather than a fixed combination.

Avoid recommending unregulated Sildalis products and report adverse reactions via the Yellow Card scheme.

Patient Counselling Points

Explain that Sildalis is an unapproved combination with unquantified risks.

Warn that marketed dosing (100mg/20mg) exceeds typical starting doses and instruct on the marketed limit of one tablet per 24 hours.

Advise against mixing with nitrates or recreational nitrates (“poppers”) and to seek immediate help for priapism lasting over four hours.

Encourage patients to discuss their purchase source and to use regulated UK pharmacies to reduce counterfeit risk.

Arrange follow‑up to assess efficacy and tolerability if the patient is using any PDE5 therapy.

Delivery Across United Kingdom

Practical Closing Advice

If a patient asks whether Sildalis is a safer or better option than standard licensed medicines, the correct clinical response is that the combination is unapproved and unstudied.

Start treatment pathways with licensed options such as sildenafil or tadalafil and adjust dose based on response and side effects under medical supervision.

Patients who have already bought Sildalis online should bring packaging and any remaining tablets to their GP or pharmacist for a medication review and to enable appropriate follow‑up.

Report any suspected adverse reactions to the Yellow Card scheme so regulators can monitor harms associated with unregulated products.

For straightforward, evidence‑based treatment for erectile dysfunction, a GP or specialist can discuss Viagra, Cialis or appropriate generics and consider cardiovascular safety before prescribing.